Functional Impairment and Disability among Patients with Migraine: Evaluation of Galcanezumab in a Long-Term, Open-Label Study

Journal: Quality of Life Research

1Janet H. Ford, 1Virginia L. Stauffer, 2Peter McAllister, 3Sreelatha Akkala, 1Matthew Sexson, 1David W. Ayer, 1Shufang Wang

1Eli Lilly and Company, Indianapolis, IN, USA
2New England Institute for Neurology and Headache, Stamford, USA
3Eli Lilly Services India Pvt Ltd, Bengaluru, India

Corresponding Author:

Janet H. Ford
Eli Lilly and Company
893 S. Delaware Street
Indianapolis, IN 46225, USA
Phone: 317-903-8199
Email: ford_janet@lilly.com
Supplementary material

Online resource: List of institutional review boards at each study site

Commissie Medische Ethiek Universitair Ziekenhuis [Institutes: Clinique St. Joseph, Algemeen Ziekenhuis St Jan Brugge, Universitair Ziekenhuis Brussel; Belgium], IRB Services [Institutes: DIEX Recherche Sherbrooke, Inc., Stroyan Research; Canada], Conjoint Medical Ethics Committee [Institute: University of Calgary, Canada], CPP Sud Mediterannée V [Institutes: CHU St Etienne Hôpital Nord, Hôpital de la Timone, Hôpital de Cimiez, Hôpital Lariboisière; France], Egyesületi Irodai Tanács [Institutes: Országos Idegügyi Iroda, Petz Aladár Megyei Orvostudományi Intézet, SE Neurologiai Klinika, Valeom Kft.; Hungary], Quorum Review, Inc. [Institutes: Wilmington Health Associates, Mercy Health Research, Blue Ridge Research Center, Jacksonville Center for Clinical Research, Ericksen Research and Development, Suburban Research Associates, California Medical Clinic for Headache, Albuquerque Neuroscience, Inc., ClinPoint Trials, LLC, Encompass Clinical Research, New England Institute for Clinical Research, Infinity Clinical Research, LLC, PharmQuest, Ponce School of Medicine CAIMED Center; USA]